Jazz Pharmaceuticals announced positive results from its HERIZON-GEA-01 trial, showing that Ziihera, combined with chemotherapy, significantly improved overall survival in adults with HER2-positive gastroesophageal adenocarcinoma (GEA) compared to the previous standard treatment. This reinforces Ziihera as the new HER2-targeted backbone therapy for first-line GEA, following its recent FDA approval. The company plans to submit these data for presentation at a major medical meeting and to global health authorities, aiming to establish Ziihera as the new standard of care.
Bitcoin's price pulled back from above $80,000 to trade near $77,600, showing short-term weakness with a risk of dropping to $74,000 support. A four-hour chart signals potential further decline if immediate support around $77,000 fails, but a longer-...
RB Global, Inc. reported an 11% increase in Q2 revenue, though adjusted EBITDA grew only 6% due to lower take rates and acquisition mix affecting operating leverage. The company gained market share in automotive gross transaction volume and strengthe...
A retired ironworker who returned to work for 40 hours on a bridge project saw his union pension suspended for that month, despite continuing to receive his Social Security benefits. Social Security stops withholding benefits after full retirement ag...
Ryman Hospitality Properties received a Buy rating due to its unique focus on group-oriented resorts and the strategic acquisition of Grande Lakes Orlando for $1.38 billion. This deal is expected to boost adjusted funds from operations (FFO) by 2027,...
Japanese firm Metaplanet transferred 800 Bitcoin worth about $62 million to Coinbase Prime, raising speculation of a potential sale. However, the move could also be for custody or liquidity management, not necessarily a sale. Despite increasing Bitco...
